50264-63-6

Usage

Uses

Used in Pharmaceutical Industry:
1-[(4-Fluorophenyl)methyl]-1H-indazole-3-carboxylic acid is used as a reactant for the preparation of cannabinoid indole and indazole compounds. These compounds are specifically designed for treating pain and nausea, offering potential therapeutic benefits to patients suffering from various conditions.
Used in Research and Forensic Applications:
As an analytical reference standard, 1-[(4-Fluorophenyl)methyl]-1H-indazole-3-carboxylic acid is utilized in forensic and research settings. It serves as a structurally classified synthetic cannabinoid, aiding in the study and analysis of its physiological and toxicological properties. 1-[(4-Fluorophenyl)methyl]-1H-indazole-3-carboxylic acid is particularly relevant in the investigation of the effects and potential risks associated with synthetic cannabinoids, such as AB-FUBINACA and its metabolites.

InChI:InChI=1/C15H11FN2O2/c16-11-7-5-10(6-8-11)9-18-13-4-2-1-3-12(13)14(17-18)15(19)20/h1-8H,9H2,(H,19,20)

Upstream product

• 459-46-1 4-Fluorobenzyl bromide 
• 43120-28-1 methyl 1H-indazole-3-carboxylate 
• 942-24-5 3-methoxycarbonylindole 

Downstream Products

• 1185282-03-4 N-[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl]-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide 
• 1185282-02-3 N-[(1S)-2-amino-2-oxo-1-phenylethyl]-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide 
• 1185282-00-1 ADB-FUBINACA 
• 1185282-01-2 N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide 
• 1185282-10-3 N-{(1S)-1-[({[5-(aminocarbonyl)-1,3,4-oxadiazol-2-yl]methyl}amino)carbonyl]-2,2-dimethylpropyl}-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide 
• 1185287-56-2 ((S)-2-{[1-(4-fluorobenzyl)-1H-indazole-3-carbonyl]-amino}-3,3-dimethylbutyryl-amino)acetic acid benzyl ester 
• 1185282-08-9 N-{[1-(4-fluorobenzyl)-1H-indazol-3-yl]carbonyl}-3-methyl-L-valylglycine 

Relevant academic research and scientific papers

MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS

Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4-dependent condition more specifically, by contacting MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having structure (I): or a pharmaceutically acceptable salt, isomer, hydrate, solvate or isotope thereof, wherein E, Q, W, Z, R1, R2, R3, and R4 are as defined herein. Pharmaceutical compositions containing such compounds, as well as compounds themselves, are also provided.

INDAZOLE DERIVATIVES AS CANNABANOID RECEPTOR PARTIAL AGONISTS

The present disclosure includes peripheral partial agonists of one or more CB receptors, including modulation of CB1, both with and without CB2 selectivity. The compounds of the present disclosure may be useful in the treatment of diseases and disorders mediated by a CB-signaling pathway, including but not limited to pain, gastrointestinal disorders, metabolic disorders, and liver disorders, such as alcoholic steatohepatitis or nonalcoholic steatohepatitis (NASH),

Pharmacology of Cumyl-Carboxamide Synthetic Cannabinoid New Psychoactive Substances (NPS) CUMYL-BICA, CUMYL-PICA, CUMYL-5F-PICA, CUMYL-5F-PINACA, and Their Analogues

Synthetic cannabinoids (SC) are the largest class of new psychoactive substances (NPS), and are increasingly associated with serious adverse effects. The majority of SC NPS are 1,3-disubstituted indoles and indazoles featuring a diversity of subunits at t

INDAZOLE DERIVATIVES

This invention relates to compounds, pharmaceutical compositions and methods for the treatment of a condition mediated by CB1 receptor activity in a mammalian subject including a human, which comprises administering to a mammal in need of such treatment a